hepatic stellate cells

[Liver International] Investigators evaluated the hypothesis that myofibroblastic (activated) hepatic stellate cells and liver fibrosis could be safely reduced by inhibiting the cysteine/glutamate antiporter xCT.

[Stem Cell Research & Therapy] The authors established mouse models of CCl4-injured liver fibrosis (LF) and administered hPMSCs at different stages of LF once a week for two weeks. The therapeutic effect of hPMSCs on LF was investigated, according to histopathological and blood biochemical analyses.

[Cell Death & Disease] Researchers investigated the Fas/FasL signaling and hepatocytes apoptosis in liver samples from both human sections and mouse models.

[Cell] Investigators provide an in-depth discussion of the underlying pathogenetic mechanisms that lead to progressive liver injury, including the metabolic origins of Nonalcoholic fatty liver disease (NAFLD), the effect of NAFLD on hepatic glucose and lipid metabolism, bile acid toxicity, macrophage dysfunction, and hepatic stellate cell activation, and consider the role of genetic, epigenetic, and environmental factors that promote fibrosis progression and risk of hepatocellular carcinoma in nonalcoholic steatohepatitis.

[Signal Transduction and Targeted Therapy] The authors postulated the hypothesis that DDR1 and its ligand might ignite the interaction between uveal melanoma (UM) cells and their surrounding niche of liver thereby conferring strengthened survival, proliferation, stemness and eventually promoting metastatic colonization in liver.

[Cell Death & Disease] Investigators found that glucocorticoid-induced leucine zipper deficiency in mice was associated with elevated CCL2 production and pro-inflammatory leukocyte infiltration at the early liver fibrosis (LF) stage, resulting in enhanced LF development.